Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Implant agent treating for solid tumor

A technology for sustained-release implants and tumors, which can be used in anti-tumor drugs, pharmaceutical formulations, active ingredients of boron compounds, etc., and can solve problems such as systemic toxicity and side effects that limit clinical applications.

Inactive Publication Date: 2008-06-25
JINAN SHUAIHUA PHARMA TECH
View PDF8 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the combination with other anticancer drugs may have a certain effect on some tumors, the systemic side effects caused by conventional administration limit its clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Put the weighed (90mg) slow-release auxiliary material (polylactic acid (PLA) with a molecular weight of 10000-20000) into the container, add a certain amount of organic solvent to dissolve and mix (subject to full dissolution), then add 10 mg of boron Tezomib, shake again and dry in vacuo to remove organic solvent. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain a slow-release implant containing 10% bortezomib. The release time of the slow-release implant in physiological saline in vitro is 15-20 days, and the release time in mouse subcutaneous is 25-30 days.

Embodiment 2

[0072]Sustained-release implants were made according to the method described in Example 1, but the anti-cancer active ingredients contained were one of the following:

[0073] (A) 1% bortezomib and 99% polylactic acid;

[0074] (B) 5% bortezomib and 95% polylactic acid;

[0075] (C) 10% bortezomib and 90% polylactic acid;

[0076] (D) 15% bortezomib and 85% polylactic acid;

[0077] (E) 20% bortezomib and 80% polylactic acid.

Embodiment 3

[0079] Put the weighed (85 mg) sustained-release excipient (PLGA with a molecular weight of 15000-30000, 50:50) into the container, add a certain amount of organic solvent to dissolve and mix (subject to complete dissolution), then add 15 mg of bortezoid m, re-shake and vacuum-dry to remove organic solvents. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain a slow-release implant containing 15% bortezomib. The release time of the sustained-release implant in physiological saline in vitro is 14-24 days, and the release time in mouse subcutaneous is 20-28 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of bortezomib and sustained-release excipients. The solid tumor includes brain tumor, liver cancer, lung cancer, oesophagus cancer, gastric cancer, breast cancer, pancreatic cancer, thyroid cancer, nasopharyngeal cancer, ovarian cancer, endometrial cancer, cervical cancer, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, skin cancer, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma rooted at a peripheral nervous system, mucosa, glands, blood vessels, bone tissues and lymph nodes. The sustained-release excipients are mainly a biological polymer which is dissoluble and can be degraded and absorbed, in the degradation and absorption process of which carmustine is sustainedly released to part of the tumor, thus the entire toxicity of the carmustine is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the carmustine but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.

Description

(1) Technical field [0001] The invention relates to a slow-release implant for treating solid tumors, belonging to the technical field of medicines. (2) Background technology [0002] Although the research on cancer has made great progress, its mortality rate is still in the forefront of various common causes of death. The latest data show that in 2006, 3 million people died of cancer in my country. The incidence of cancer is increasing year by year and tends to be younger. Statistics show that in less than 20 years, the incidence of cancer in my country has increased by 69%, and the mortality rate has increased by 29.4%. According to the latest statistics from the World Health Organization, the global cancer incidence rate will increase by 50% by 2020, and the number of patients will increase to 15 million. It is estimated that 4 million people will die of cancer every year in my country in 2020. Therefore, exploring an effective method or drug for treating cancer has bec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/69A61K47/34A61P35/00
Inventor 孙娟姜俊敏
Owner JINAN SHUAIHUA PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products